"mRNA vaccine technology offers advantages in efficacy, speed of development, and production scalability and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic," Moderna CEO Stephane Bancel said.
Federal government awards Moderna $176 million in push for bird-flu shot
→
Mr. Bancel said he could not make those guarantees.
Moderna CEO Stephane Ban defends COVID vaccine price hike, citing pivot to endemic phase
→
